4.7 Review

Mitochondrial dysfunction in diabetes and the regulatory roles of antidiabetic agents on the mitochondrial function

期刊

JOURNAL OF CELLULAR PHYSIOLOGY
卷 234, 期 6, 页码 8402-8410

出版社

WILEY
DOI: 10.1002/jcp.27754

关键词

antidiabetic agents; diabetic complications; diabetes mellitus; mitochondria; mitochondrial dysfunction

向作者/读者索取更多资源

The prevalence of type 2 diabetes mellitus (T2DM) is increasing rapidly with its associated morbidity and mortality. Many pathophysiological pathways such as oxidative stress, inflammatory responses, adipokines, obesity-induced insulin resistance, improper insulin signaling, and beta cell apoptosis are associated with the development of T2DM. There is increasing evidence of the role of mitochondrial dysfunction in the onset of T2DM, particularly in relation to the development of diabetic complications. Here, the role of mitochondrial dysfunction in T2DM is reviewed together with its modulation by antidiabetic therapeutic agents, an effect that may be independent of their hypoglycemic effect.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Cell Biology

Sodium-glucose co-transporter 2 inhibitors and hematopoiesis

Habib Yaribeygi, Mina Maleki, Fatemeh Nasimi, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar

Summary: SGLT2 inhibitors may enhance hematopoiesis and stimulate erythropoiesis in diabetic patients, potentially providing additional benefits.

JOURNAL OF CELLULAR PHYSIOLOGY (2022)

Review Biochemistry & Molecular Biology

Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus

Habib Yaribeygi, Mina Maleki, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar

Summary: Type 2 diabetes is a major cause of mortality and morbidity worldwide, often leading to long-term complications such as diabetic nephropathy. Preventing and delaying the development of diabetic nephropathy is a key goal in managing patients with type 2 diabetes. Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, has been shown to have renoprotective effects in patients with type 2 diabetes. This study reviews the available clinical data on the potential renoprotective effects of empagliflozin from a mechanistic and molecular perspective.

CURRENT MEDICINAL CHEMISTRY (2023)

Article Pharmacology & Pharmacy

Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity

Habib Yaribeygi, Mina Maleki, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar

Summary: Epicardial adipose tissue plays a physiological role in normal heart function, but can become a cardiac risk factor in pathological conditions. Recent studies suggest that SGLT2 inhibitors can modulate epicardial adiposity and reduce the risk of cardiac complications in diabetic patients.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2023)

Review Biochemistry & Molecular Biology

New insights into cellular links between sodium-glucose cotransporter-2 inhibitors and ketogenesis

Habib Yaribeygi, Mina Maleki, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar

Summary: SGLT2 inhibitors are a new class of antidiabetic drugs that normalize hyperglycemia through urinary glucose excretion. However, they may cause side effects such as ketoacidosis, which can negatively affect their therapeutic benefits. In this study, we present the current knowledge and shed light on the cellular pathways involved, aiming to prevent adverse side effects in diabetic patients treated with these drugs.

JOURNAL OF CELLULAR BIOCHEMISTRY (2022)

Review Biochemistry & Molecular Biology

Benefits of GLP-1 Mimetics on Epicardial Adiposity

Habib Yaribeygi, Mina Maleki, Fatemeh Nasimi, Tannaz Jamialahmadi, Fatima C. Stanford, Amirhossein Sahebkar

Summary: The epicardial adipose tissue, known as the adipose tissue surrounding the myocardium, can cause cardiovascular problems through various mechanisms. Controlling its volume and thickness, especially in diabetic patients, is crucial. Incretin-based drugs, as newly developed antidiabetics, have the potential to reduce cardiovascular risks by regulating epicardial adiposity. This study aims to evaluate the impact of incretin-based drugs on both physiological and pathological epicardial adiposity.

CURRENT MEDICINAL CHEMISTRY (2023)

Review Pharmacology & Pharmacy

Sodium-glucose cotransporter 2 inhibitors: A comprehensive review from cells to bedside

Bahador Bagheri, Habib Yaribeygi, Erfan Taherifard, Azita Hajhossein Talasaz, Haleh Bagheri, Mahboubeh Darban, Reza Tabrizi, Siamak Najafi, Mahmoud Khodadost, Maryam Akbari

Summary: SGLT2 inhibitors have shown promise as new medications for cardiovascular and kidney diseases, in addition to their approved use for type 2 diabetes. However, the mechanisms underlying these new benefits are not fully understood.

FUNDAMENTAL & CLINICAL PHARMACOLOGY (2023)

Review Medicine, General & Internal

Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu

Habib Yaribeygi, Mina Maleki, Zeljko Reiner, Tannaz Jamialahmadi, Amirhossein Sahebkar

Summary: Chronic hyperglycemia in diabetes leads to dyslipidemia, which is a major risk factor for complications such as atherosclerosis and coronary heart disease. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, in addition to their hypoglycemic effects, have been shown to potentially improve lipid metabolism and prevent dyslipidemia-induced complications. However, the exact mechanisms of these benefits are not fully understood.

JOURNAL OF CLINICAL MEDICINE (2022)

Review Biochemistry & Molecular Biology

SGLT2 inhibitors and autophagy in diabetes

Habib Yaribeygi, Mina Maleki, Stephen L. Atkin, Tannaz Jamialahmadi, Amirhossein Sahebkar

Summary: Autophagy is a dual process that can promote cell survival and efficiency in normal conditions but become pathological in disease states such as diabetes. Chronic hyperglycemia induces aberrant autophagy and leads to cellular death, which is a major underlying cause of diabetes-related complications. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are newly introduced antidiabetic drugs that may have additional benefits beyond glycemic control, but their effect on autophagy remains unclear. This review aims to elucidate the potential effects of SGLT2is on autophagy.

CELL BIOCHEMISTRY AND FUNCTION (2023)

Review Biochemistry & Molecular Biology

Anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors in COVID-19

Habib Yaribeygi, Mina Maleki, Stephen L. Atkin, Prashant Kesharwani, Tannaz Jamialahmadi, Amirhossein Sahebkar

Summary: COVID-19 is a systemic inflammatory disorder, and patients with underlying chronic inflammatory diseases like diabetes mellitus are at high risk of severe complications. Preventing or suppressing inflammation is crucial in diabetic patients. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are new anti-diabetic drugs with hypoglycemic effects and potential anti-inflammatory properties. Although there is no direct data in diabetic patients with COVID-19, evidence suggests that SGLT2i can reduce systemic inflammation and the cytokine storm effect through various cellular mechanisms. This review aims to categorize and describe the molecular and cellular pathways by which SGLT2i exert anti-inflammatory effects in diabetic patients with COVID-19.

IUBMB LIFE (2023)

Article Medicine, General & Internal

Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Increases Antioxidative Capacity and Improves Renal Function in Diabetic Rats

Habib Yaribeygi, Mohammad Amin Hemmati, Fatemeh Nasimi, Mina Maleki, Tannaz Jamialahmadi, Ivan Reiner, Zeljko Reiner, Amirhossein Sahebkar

Summary: Diabetic nephropathy involves oxidative stress as one of the main pathologic mechanisms. This study aimed to evaluate the effects of the SGLT2 inhibitor empagliflozin on oxidative stress and renal function in diabetes. Results showed that empagliflozin improved renal function by reducing urea, uric acid, and creatinine levels, increasing antioxidant capacity, and reducing oxidative damage.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Endocrinology & Metabolism

Saffron and crocin ameliorate prenatal valproic acid-induced autistic-like behaviors and brain oxidative stress in the male offspring rats

Seyed Ali Seyedinia, Parnia Tarahomi, Davood Abbarin, Katayoun Sedaghat, Ali Rashidy-Pour, Habib Yaribeygi, Abbas Ali Vafaei, Payman Raise-Abdullahi

Summary: This study aimed to determine the effects of saffron extract and crocin on brain oxidative stress and behavioral, motor, and cognitive deficits in an animal model of autism. The results showed that saffron and crocin can alleviate behavioral abnormalities, reduce brain oxidative stress levels, and hold promise as herbal-based pharmacological treatments for individuals with autism.

METABOLIC BRAIN DISEASE (2023)

Review Biology

HEPATIC BENEFITS OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS IN LIVER DISORDERS

Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, Seyed Adel Moallem, Amirhossein Sahebkar

Summary: Diabetic patients are more prone to liver dysfunction, making it crucial to use hypoglycemic agents to improve liver efficiency. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lowering effects. Recent evidence suggests that they may have extra-glycemic benefits and can potentially protect the liver against different hepatic disorders. This review discusses the current knowledge about the effects of SGLT2 inhibitors on various forms of liver complications and the underlying mechanisms.

EXCLI JOURNAL (2023)

Review Biology

BRAIN INSULIN SIGNALING AND COGNITION: POSSIBLE LINKS

Habib Yaribeygi, Mina Maleki, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar

Summary: Poor cognitive ability is a growing health problem in the elderly and patients with diabetes, and the underlying cause is not well-defined. Recent studies have suggested a possible link between brain insulin signaling and cognitive ability, as insulin has extrametabolic impacts on neuronal circuits. This review discusses the role of brain insulin signaling in cognition and explores potential connections between brain insulin signaling and cognitive ability.

EXCLI JOURNAL (2023)

Review Biology

SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AND MITOCHONDRIAL FUNCTIONS: STATE OF THE ART

Habib Yaribeygi, Mina Maleki, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar

Summary: SGLT2is, a class of newly introduced antidiabetic drugs, have potent hypoglycemic effects and may also provide additional non-glycemic benefits, including the improvement of mitochondrial function.

EXCLI JOURNAL (2022)

Review Biology

MOLECULAR MECHANISMS LINKING STRESS AND INSULIN RESISTANCE

Habib Yaribeygi, Mina Maleki, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar

Summary: There is strong evidence supporting the relationship between stress and insulin resistance. Stress can impair glucose homeostasis through multiple molecular pathways, potentially leading to the development of diabetes.

EXCLI JOURNAL (2022)

暂无数据